Tissue Regenix Group PLC DermaPure® secures first GPO contract in US (9007C)

TIDMTRX

RNS Number : 9007C

Tissue Regenix Group PLC

01 July 2016

Tissue Regenix Group plc

DermaPure(R) secures first GPO contract in US

York, 1 July 2016 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company announces that Tissue Regenix Wound Care, Inc. has secured a contract agreement with a national US Group Purchasing Organization (GPO) for the use of DermaPure(R).

A GPO negotiates contracts and pricing with an Integrated Delivery Network (IDN) on behalf of its members which can include; regional alliances, hospitals and individual physician offices.

Effective from today, Tissue Regenix Wound Care Inc. secured a 3-year contract agreement with a national GPO which spans across 43 states and is affiliated with 48 IDNs, with a membership comprised of more than 800 acute care hospitals, 186 different Health Systems and more than 1000 long-term care facilities. This agreement now makes it easier for physicians within these facilities to access DermaPure(R) for the treatment of their patients.

Greg Bila, President Tissue Regenix Wound Care, Inc. commented: 'This first GPO agreement marks another significant milestone for DermaPure(R), allowing a multitude of care settings and physicians to access the product. The results and clinical support that we have seen, to date, has been outstanding and we are pleased to be able to convert this into further market penetration and availability.'

For more Information:

 
 Tissue Regenix Group plc                    Tel: 0330 
  Caitlin Pearson Corporate Communications    430 3073 
  Officer 
==========================================  =========== 
 Jefferies International Ltd                 Tel: 020 
  Simon Hardy / Harry Nicholas                7029 8000 
==========================================  ===========

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL(R)') technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', as part of its commercialisation strategy for its dCELL(R) technology platform.

This information is provided by RNS

The company news service from the London Stock Exchange

END

CNTSDEEFSFMSEFM

(END) Dow Jones Newswires

July 01, 2016 02:00 ET (06:00 GMT)

Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jul 2024 to Aug 2024